BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26110882)

  • 1. Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival.
    Parikh RR; Grossbard ML; Harrison LB; Yahalom J
    Leuk Lymphoma; 2016 Feb; 57(2):320-327. PubMed ID: 26110882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stage-specific roles of radiotherapy and chemotherapy in nodular lymphocyte predominant Hodgkin lymphoma patients: a propensity score-matched analysis of the SEER database.
    Wang S; Jia M; Han J; Zhang R; Huang K; Qiao Y; Chen P; Fu Z
    Cancer Med; 2021 Jan; 10(2):540-551. PubMed ID: 33249743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Radiation in All Stages of Nodular Lymphocytic Predominant Hodgkin Lymphoma.
    Odei B; Boothe D; Frandsen J; Poppe MM; Gaffney DK
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):819-824. PubMed ID: 29051078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival.
    Alonso C; Dutta SW; Mitra N; Landsburg DJ; Zaorsky NG; Grover S; Peterson J; Trifiletti DM
    Cancer Med; 2018 Apr; 7(4):1118-1126. PubMed ID: 29479868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes in patients with early stage nodular lymphocyte-predominant Hodgkin's lymphoma treated with radiotherapy.
    Solanki AA; LeMieux MH; Chiu BC; Mahmood U; Hasan Y; Koshy M
    PLoS One; 2013; 8(9):e75336. PubMed ID: 24058675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
    Binkley MS; Rauf MS; Milgrom SA; Pinnix CC; Tsang R; Dickinson M; Ng AK; Roberts KB; Gao S; Balogh A; Ricardi U; Levis M; Casulo C; Stolten M; Specht L; Plastaras JP; Wright C; Kelsey CR; Brady JL; Mikhaeel NG; Hoppe BS; Terezakis SA; Picardi M; Della Pepa R; Kirova Y; Akhtar S; Maghfoor I; Koenig JL; Jackson C; Song E; Sehgal S; Advani RH; Natkunam Y; Constine LS; Eich HT; Wirth A; Hoppe RT
    Blood; 2020 Jun; 135(26):2365-2374. PubMed ID: 32211877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma.
    Parikh RR; Grossbard ML; Harrison LB; Yahalom J
    Radiother Oncol; 2016 Jan; 118(1):52-9. PubMed ID: 26522061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
    Lazarovici J; Dartigues P; Brice P; Obéric L; Gaillard I; Hunault-Berger M; Broussais-Guillaumot F; Gyan E; Bologna S; Nicolas-Virelizier E; Touati M; Casasnovas O; Delarue R; Orsini-Piocelle F; Stamatoullas A; Gabarre J; Fornecker LM; Gastinne T; Peyrade F; Roland V; Bachy E; André M; Mounier N; Fermé C
    Haematologica; 2015 Dec; 100(12):1579-86. PubMed ID: 26430172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
    van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
    Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.
    Pinnix CC; Milgrom SA; Cheah CY; Gunther JR; Ludmir EB; Wogan CF; Nastoupil LJ; Neelapu SS; Westin J; Lee HJ; Iyer SP; Steiner RE; Fayad LE; Fowler NH; Wang ML; Samaniego F; Rodriguez MA; Rich AE; Medeiros LJ; Dabaja BS
    Blood Adv; 2019 May; 3(9):1356-1367. PubMed ID: 31036721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
    J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
    Olszewski AJ; Shrestha R; Cook NM
    Cancer; 2015 Oct; 121(19):3472-80. PubMed ID: 26149294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy.
    Parikh RR; Yahalom J
    Leuk Lymphoma; 2017 Mar; 58(3):614-622. PubMed ID: 27685446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early-Stage Classic Hodgkin Lymphoma: The Utilization of Radiation Therapy and Its Impact on Overall Survival.
    Parikh RR; Grossbard ML; Harrison LB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):684-93. PubMed ID: 26279323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Binkley MS; Flerlage JE; Savage KJ; Akhtar S; Steiner R; Zhang XY; Dickinson M; Prica A; Major A; Hendrickson PG; Hopkins D; Ng A; Casulo C; Baron J; Roberts KB; Al Kendi J; Balogh A; Ricardi U; Torka P; Specht L; De Silva R; Pickard K; Blazin LJ; Henry M; Smith CM; Halperin D; Brady J; Brennan B; Senchenko MA; Reeves M; Hoppe BS; Terezakis S; Talaulikar D; Picardi M; Kirova Y; Fergusson P; Hawkes EA; Lee D; Doo NW; Barraclough A; Cheah CY; Ku M; Hamad N; Mutsando H; Gilbertson M; Marconi T; Viiala N; Maurer MJ; Eichenauer DA; Hoppe RT;
    J Clin Oncol; 2024 Mar; ():JCO2301655. PubMed ID: 38531001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East.
    Akhtar S; Rauf MS; Khafaga Y; Al-Kofide A; Elhassan TAM; Elshenawy MA; Nadri J; Mushtaq AH; Bakshi N; Shamayel M; Al-Sweedan S; Sarwar S; Maghfoor I
    BMC Cancer; 2021 Apr; 21(1):351. PubMed ID: 33794818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
    Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
    Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma.
    Parikh RR; Grossbard ML; Harrison LB; Yahalom J
    Leuk Lymphoma; 2016 May; 57(5):1074-82. PubMed ID: 26374099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
    Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
    Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.